Aurinia Pharmaceuticals Inc. announced positive results for its phase III clinical trial for voclosporin, a treatment for active lupus nephritis, a life-threatening complication of lupus. The study met all of its primary and secondary endpoints, leading to complete remission in a signficant number of participants. Yourway is encouraged by this major breakthrough, the first therapy specifically approved for lupus-related kidney disease, and the tremendous benefits it will have for this patient population.